Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Molloy, E.
Right arrow Articles by Barry, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molloy, E.
Right arrow Articles by Barry, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 522-523
Rheumatology Vol. 43 No. 4 (c) British Society for Rheumatology 2004; all rights reserved

Letter to the Editor

Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab

E. Molloy, S. Ramakrishnan, E. Murphy and M. Barry

Department of Rheumatology, James Connolly Memorial Hospital, Blanchardstown, Dublin 15, Ireland

Correspondence to: M. Barry. E-mail: mbarry@ireland.com

The first 10% of the full text of this article appears below.

SIR, Three anti-tumour necrosis factor (TNF) agents (infliximab, adalimumab and etanercept) have demonstrated impressive efficacy in the treatment of rheumatoid arthritis (RA). They have been remarkably safe in the clinical trials reported to date [1]. The occurrence of serious infection, some fatal, during anti-TNF therapy in three UK centres led Moots et al. [2] to advocate greater caution in the use of these agents. Others have also recently emphasized the risk of serious bacterial infection associated with anti-TNF therapy [3, 4]. As of August 2002, 574 deaths have occurred in 554 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?